75 citations · 177 across the 11 of their papers we have counts for
11 papers
Optimal Bayesian hierarchical model to accelerate the development of tissue-agnostic drugs and basket trials
Liyun Jiang, Lei Nie, Fangrong Yan +1
Tissue-agnostic trials enroll patients based on their genetic biomarkers, not tumor type, in an attempt to determine if a new drug can successfully treat disease conditions based o…
Elastic Priors to Dynamically Borrow Information from Historical Data in Clinical Trials
Liyun Jiang, Lei Nie, Ying Yuan
Use of historical data and real-world evidence holds great potential to improve the efficiency of clinical trials. One major challenge is how to effectively borrow information from…
Incorporating historical information to improve phase I clinical trial designs
Yanhong Zhou, J. Jack Lee, Shunguang Wang +2
Incorporating historical data or real-world evidence has a great potential to improve the efficiency of phase I clinical trials and to accelerate drug development. For model-based…
TOP: Time-to-Event Bayesian Optimal Phase II Trial Design for Cancer Immunotherapy
Ruitao Lin, Robert L Coleman, Ying Yuan
Immunotherapies have revolutionized cancer treatment. Unlike chemotherapies, immune agents often take longer time to show benefit, and the complex and unique mechanism of action of…
Time-to-Event Model-Assisted Designs to Accelerate Phase I Clinical Trials
Ruitao Lin, Ying Yuan
Two useful strategies to speed up drug development are to increase the patient accrual rate and use novel adaptive designs. Unfortunately, these two strategies often conflict when…
Statistical Properties of the Keyboard Design with Extension to Drug-Combination Trials
Haitao Pan, Ruitao Lin, Ying Yuan
The keyboard design is a novel phase I dose-finding method that is simple and has good operating characteristics. This paper studies theoretical properties of the keyboard design,…